Meta-Analysis of Randomised Controlled Trials on the Efficacy of Direct Oral Anticoagulants in Left Ventricular Thrombosis: An Updated Perspective.

Heart Lung CircJul 2, 2026 (epub)
Clinical ResearchCardiology

Bernardo Resende, Mariana Simões, Gonçalo Ferraz-Costa et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis evaluated the efficacy and safety of direct oral anticoagulants (DOACs) versus warfarin in managing left ventricular thrombosis (LVT) across seven randomized controlled trials involving 553 patients. The analysis found no significant differences in overall thrombus resolution or major bleeding events, with risk ratios of 1.00 and 0.54, respectively.

Key findings

  • Overall thrombus resolution was similar between DOACs and warfarin (RR=1.00).
  • Major bleeding events were not significantly different (RR=0.54).
  • 1-month thrombus resolution showed no significant difference (RR=1.35).
  • 3-month thrombus resolution also showed no significant difference (RR=1.00).

Why it matters

Understanding the comparative effectiveness and safety of DOACs versus warfarin in LVT management is crucial for optimizing treatment strategies and improving patient outcomes, especially given the complexities associated with anticoagulation therapy.

Source

PubMed · PMID 42392916

Published in Heart Lung Circ. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.